California Proposition 38 would authorize $8.4 billion in general obligation bonds for immunology and immunotherapy research, with roughly half directed to a University of California-affiliated institute meeting specific criteria and the remainder allocated via competitive grants to other public and nonprofit institutions, prioritizing work on cancer, heart disease, and Alzheimer’s. Trader sentiment reflects a narrow edge for rejection amid concerns over long-term General Fund repayment costs estimated at roughly $500 million annually for 25 years, provisions that appear structured to favor one existing nonprofit institute backed by major donors, and uncertainty over whether royalty or licensing revenues will offset debt. Counterbalancing factors include endorsements from patient advocacy groups, requirements for price discounts on resulting treatments sold in California, and arguments that the measure could accelerate medical breakthroughs amid federal research funding pressures. Upcoming campaign spending reports, independent polling, and any new fiscal analyses before the November 2026 vote could shift probabilities in either direction.